Summary
Angiotensin Ii has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Sickle Cell Disease would be drug repurposing rather than first-in-human development. This does not mean it is approved for Sickle Cell Disease. ClinicalTrials.gov lists 2 registered trials linking Angiotensin Ii to Sickle Cell Disease: 1 has completed; 1 is terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 2 (NCT03944447). It plans or enrolled 200000 participants. Registration activity spans 2018 to 2019. No published literature item is linked to Angiotensin Ii and Sickle Cell Disease in the OSMF database yet, so the record rests on registry entries alone. Registry entries describe intent to study, not outcomes.
The RepurpOS disease-intelligence file for Sickle Cell Disease ranks 50 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: No spontaneous remission; progressive organ damage; median survival historically 40-60 years but improving; vaso-occlusive crises (VOC) in 1-4 per year average.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 25.5 (trials 5.5, literature 0.0, tier 15, approved bonus 5.0) |
| Registered trials | 2 total: 0 recruiting, 0 active / not yet recruiting, 1 completed, 1 other |
| Linked publications | 0 |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | agonist |
| Data sources | DGIdb |
| Linked via biomarker / target | AGTR1 |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT04053764 | Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease Caused by Sickle Cell Disease 2019 | completed | Phase 2 | 58 |
| NCT03944447 | Outcomes Mandate National Integration With Cannabis as Medicine 2018 | status unknown | Phase 2 | 200,000 |
Published literature
No publication is linked to this pair yet.
Mechanism and notes
Recorded mechanism or class: agonist.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target AGTR1. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Angiotensin Ii approved for Sickle Cell Disease?
Angiotensin Ii has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Sickle Cell Disease would be drug repurposing rather than first-in-human development. This does not mean it is approved for Sickle Cell Disease. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Angiotensin Ii in clinical trials for Sickle Cell Disease?
ClinicalTrials.gov lists 2 registered trials linking Angiotensin Ii to Sickle Cell Disease: 1 has completed; 1 is terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 2 (NCT03944447). It plans or enrolled 200000 participants. Registration activity spans 2018 to 2019.
What does the evidence show for Angiotensin Ii in Sickle Cell Disease?
Angiotensin Ii has 1 completed registered trial for Sickle Cell Disease but no linked publication, which usually means results are unpublished, pending, or not yet matched to this record. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target AGTR1. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-06. Page built 2026-10-07.